Literature DB >> 3440930

Effect of bile salts on nasal permeability in vitro.

S J Hersey1, R T Jackson.   

Abstract

Nasal mucosa excised from dogs or rabbits was mounted as a flat sheet in an in vitro chamber. The permeability was assessed by measuring the unidirectional flux of the radiolabeled tracer compounds, water, sucrose, polyethylene glycol, and cholecystokinin octapeptide. The permeability coefficients calculated from the fluxes indicate that the nasal mucosa is moderately permeable to water-soluble compounds and compares with ileum or gallbladder. The addition of 0.5% sodium deoxycholate to the mucosal bathing solution caused a rapid, four- to fivefold increase in permeability to sucrose or cholecystokinin octapeptide. The increase in permeability was bidirectional, was not reversed by washing, and was accompanied by histological evidence of extensive loss of the surface epithelial layer. These results indicate that bile salts enhance nasal permeability by removing the epithelial cells, which constitute a major permeability barrier, rather than causing a chemical modification of the mucosal cells. This argues against the use of bile salts to enhance nasal drug absorption in patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3440930     DOI: 10.1002/jps.2600761206

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.

Authors:  A E Pontiroli; E Pajetta; A Calderara; M Alberetto; G Pozza; V Manganelli; G Resmini; L Tessari; V Maresca
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

2.  Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation.

Authors:  R Ricciardi; B Rossi; M Nicora; A Sghirlanzoni; A Muratorio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

3.  Bile salt-fatty acid mixed micelles as nasal absorption promoters of peptides. II. In vivo nasal absorption of insulin in rats and effects of mixed micelles on the morphological integrity of the nasal mucosa.

Authors:  P Tengamnuay; A K Mitra
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

Review 4.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

5.  Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects.

Authors:  T Kissel; J Drewe; S Bantle; A Rummelt; C Beglinger
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

6.  Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats.

Authors:  A Yamamoto; T Taniguchi; K Rikyuu; T Tsuji; T Fujita; M Murakami; S Muranishi
Journal:  Pharm Res       Date:  1994-10       Impact factor: 4.200

7.  Nasal absorption in the rat. III. Effect of lysophospholipids on insulin absorption and nasal histology.

Authors:  S G Chandler; N W Thomas; L Illum
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

8.  In vitro nasal transport across ovine mucosa: effects of ammonium glycyrrhizinate on electrical properties and permeability of growth hormone releasing peptide, mannitol, and lucifer yellow.

Authors:  P M Reardon; C H Gochoco; K L Audus; G Wilson; P L Smith
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

9.  The effects of permeation enhancers on the surface morphology of the rat nasal mucosa: a scanning electron microscopy study.

Authors:  R D Ennis; L Borden; W A Lee
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

10.  Lack of effect of ammonium glycyrrhizinate on the morphology of ovine nasal mucosa in vitro.

Authors:  P M Reardon; D A Wall; T K Hart; P L Smith; C H Gochoco
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.